SHP2, a cytoplasmic protein-tyrosine phosphatase encoded by the PTPN11 gene, plays a critical role in developmental hematopoiesis in the mouse, and gain-of-function mutations of SHP2 are associated with hematopoietic malignancies. However the role of SHP2 in adult hematopoiesis has not been addressed in previous studies. In addition the role of SHP2 in human hematopoiesis has not been described. These questions are of considerable importance given interest in development of SHP2 inhibitors for cancer treatment. We used shRNAmediated inhibition of SHP2 expression to investigate the function of SHP2 in growth factor (GF) signaling in normal human CD34+ cells. SHP2 knockdown resulted in markedly reduced proliferation and survival of cells cultured with GF, and reduced colony forming cell growth. Cells expressing gain-of-function SHP2 mutations demonstrated increased dependency on SHP2 expression for survival compared to cells expressing wild-type Shp2. SHP2 knockdown was associated with significantly reduced myeloid and erythroid differentiation with retention of CD34+ progenitors with enhanced proliferative capacity. Inhibition of SHP2 expression initially enhanced and later inhibited STAT5 phosphorylation and reduced expression of the antiapoptotic genes MCL1 and BCLXL. These results indicate an important role for SHP2 in STAT5 activation and GF mediated proliferation, survival and differentiation of human progenitor cells.
Introduction
SHP2 is a cytoplasmic protein-tyrosine phosphatase encoded by the PTPN11 gene. SHP2 contains two tandem Src homology 2 (SH2) domains (N-SH2 and C-SH2), a protein tyrosine phosphatase (PTP) domain and a C-terminal tail. 1 In its inactive state, SHP2 has a low basal PTP activity due to autoinhibition by association of its N-SH2 domain with the PTP domain, which blocks substrate access. SHP2 directly or indirectly associates with activated receptor protein tyrosine kinases or cytokine receptors via its two SH2 domains. Binding of SH2 domains to phosphotyrosine sites on other proteins alters the conformation of the N-SH2 domain, preventing its binding to PTP domain and causing catalytic activation. Several studies indicate that SHP2 promotes activation of the Ras and ERK pathway by growth factors (GF) and cytokines. 2, 3 SHP2 is widely expressed, with high levels of expression in hematopoietic cells. In murine models, SHP2 has been found to play an essential role in hematopoietic cell development.
Homozygous deletion of SHP2 results in embryonic lethality due to severe defects in gastrulation and mesodermal patterning. 4 SHP2-deficient embryonic stem (ES) cells exhibit severely decreased differentiation to erythroid and myeloid progenitors in vitro 5, 6 and fail to contribute to both erythroid and myeloid lineages in chimeric mice derived from SHP2 -/-ES cells and wild type embryos. 7 Reintroduction of wild-type SHP2 into SHP2 -/-ES cells partially rescued these hematopoietic defects. In addition, SHP2 loss-of-function causes a block of lymphocyte development before Pro-T and Pro-B stages. 8 Altogether, these data suggests that SHP2 plays a positive role in the development of all blood cell lineages from ES cells, functioning at a very early stage of hematopoietic development. SHP2 haploinsufficiency causes a competitive repopulating defect of HSC in mice. 9 Further evidence for the importance of SHP2 in hematopoietic regulation comes from the identification of PTPN11 germ line mutations in individuals with Noonan syndrome (NS) and LEOPARD syndrome, development disorders For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From associated with abnormal hematopoiesis. 10 Somatic gain-of-function PTPN11 mutations are seen in ~ 35% of juvenile myelomonocytic leukemia (JMML). 11 PTPN11 mutations are also seen in childhood myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML). 11 These gain-of-function mutations can induce aberrant hyperactivation of the Ras-ERK pathway and GF independent growth and hypersensitivity to GF stimuli in hematopoietic cells. [12] [13] [14] Increased SHP2 expression has also been observed in acute leukemia specimens, and a potential role in leukemogenesis has been suggested. 15 Despite the essential role for SHP2 in hematopoietic development in mice, and association of SHP2 mutations with myeloid malignancies, is not clear whether SHP2 plays a critical role in normal adult hematopoiesis. It is recognized that genes that are essential at the developmental stage may not be equally critical to adult hematopoiesis. In vitro studies using factor-dependent hematopoietic cell lines indicate that SHP2 participates in signal transduction from a variety of hematopoietic GF receptors, including stem cell factor (SCF), interleukin-3 (IL-3), granulocytemacrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF) and erythropoietin. [16] [17] [18] [19] [20] [21] [22] It was recently reported that SHP2 contributes to ERK activation by G-CSF but not M-CSF. Pharmacological inhibition of SHP2 specifically inhibited CFU-G while sparing CFU-M. 23 However these studies do not address the broader role of SHP2 in regulating progenitor cell growth. Moreover murine hematopoietic cells may differ in their regulation from their human counterparts, and the role of SHP2 in human hematopoietic progenitors has not been described. Investigation of the effect of SHP2 on human hematopoiesis is of considerable significance since there is considerable interest in the development of SHP2 inhibitory compounds for treatment of leukemias and other malignancies, and hematological toxicities may be a major concern. Here we investigated the function of SHP2 in regulation of GF responsiveness in normal human hematopoietic stem and progenitor cells by inhibiting SHP2 expression in human cord blood (CB) CD34+ cells with stable SHP2 shRNA expression. Our shRNA separated by a 9-base loop, and a terminator of 6 thymidines was constructed by PCR as previously described. 24 The resulting shRNA construct was verified by automated DNA sequencing and inserted upstream of the SF promoter of DsRED in the pHIV7-SF-DsRED vector ( Fig 1A) .
MIG-R1 vectors expressing wild type SHP2 (SHP2-WT) and a gain-of- Mononuclear cells were isolated using Ficoll-Hypaque density gradient separation. Cells were either used when freshly obtained or were cryopreserved in DMSO-containing medium in liquid nitrogen tanks (vapor phase). Frozen cells were thawed and incubated in IMDM supplemented with 20% FBS and DNase I (Sigma) for 3 hour incubation at 37°C prior to further processing. CD34+ cells were selected using immunomagnetic column separation (Miltenyi) as previously described. 27 Lentivirus transduction of human CD34+ cells. CD34+ cells transduction was performed as previously described. 26 Briefly cells were cultured for 48 hours in serum-free medium (SFM, Stem Cell Technologies, Vancouver, British Columbia, Canada) with 100 ng/ml Flt-3 ligand (FL), 50 ng/ml stem cell factor (SCF), 100 ng/ml thrombopoietin (TPO), 10 ng/ml interleukin-6 (IL6), and 25 ng/ml interleukin-3 (IL3) on Fibronectin CH-296 peptide (Retronectin; Pan Vera, Madison, WI) coated plates. Cell were then resuspended in virus supernatant [multiplicity of infection (MOI) = 5~10] with the same GF and plated on Retronectin-coated plates pre-exposed to viral supernatants. This procedure was repeated after 24 hours. Forty eight hours later cells were labeled with anti-CD34-APC antibodies (Becton Dickinson, San Jose, CA), and CD34 + DsRED + cells collected by flow cytometry sorting (MoFlo, Cytomation Inc., Fort Collins, CO). CD34+ cells used for in vivo repopulation assays were transduced using a similar protocol.
For personal use only. on April 16, 2017. by guest www.bloodjournal.org From Cord blood CD34 + cells were cultured for 24 hours in serum-free medium with 100 ng/ml FL, 100 ng/ml SCF and 100 ng/ml TPO on Fibronectin CH-296 peptide coated plates. Cell were then resuspended in virus supernatant (multiplicity of infection = 10) with the same GF and plated on Retronectin-coated plates pre-exposed to viral supernatants. This procedure was repeated after 24 hours. Forty eight hours later cells were labeled with anti-CD34-APC antibodies and CD34 + DsRED + cells were collected by flow cytometry sorting for transplantation.
TF-1 cells cultured in RMPI1640 supplemented with 10% FBS and 2ng/ml GM-CSF were exposed to retroviral particles carrying MIG-R1, SHP2-WT, SHP2-shR or SHP2-E76K at MOI=2 and GFP+ cells were selected 48 hours later by flow cytometry sorting. GFP+ TF-1 cells were expanded in culture and transduced with lentiviral vectors expressing sh-Ctrla or sh-Shp2-2 at MOI of 2. GFP+DsRED+ cells were isolated by flow cytometry sorting 48 hours after transduction.
Evaluation of Progenitor Growth
Colony formation (CFC) assay. CD34+DsRED+ cells were plated in methylcellulose progenitor culture and assessed for the presence of CFU-GM, and CFU-E colonies as described previously. 28 Cell expansion in Liquid Culture with high GFs. CD34+DsRED+ cells were cultured in IMDM with 30% FBS and GFs [EPO (3u/ml); SCF (5ng/ml); granulocyte-macrophage colony stimulating factor (GM-CSF) (20ng/ml); granulocyte colony stimulating factor (G-CSF) (20ng/ml) and IL-3 (5ng/ml)] as used in CFC culture. Cellular expansion was measured by counting the number of cells generated in culture at different time points as described in the results. Protein extracts were prepared as previously described. 26 In vivo repopulation assays. All animal studies were performed in accordance with the guidelines of the City of Hope Research Animal Care Committee. NOD/SCID/γ chain null (NSG) mice (Jackson Laboratory, Bar Harbor, ME) were housed in micro-insulator cages in a pathogen-free condition and handled in laminar flow hoods. 6-8 week-old NSG mice were sublethally irradiated with 300 cGy from a 137 Cs source with attenuator on the day of transplantation and placed on Sulfatrim water after irradiation. 5 x 10 4 to 2 x 10 5 CD34 + DsRED + cells were transplanted into NSG mice by tail vein injection. Bone marrow cells from both femurs were harvested from each mouse 8 to 14 weeks after transplantation and human CD45+ cells was detected using flow cytometry.
Statistics. Data obtained from multiple experiments were reported as the mean + SEM.
Significance levels were determined by Student's t test and ANOVA analysis. Data from NSG mice engraftment experiment were analyzed using non-parametric Mann Whitney test.
Results
Effective SHP2 knockdown in CD34+ cells using lentivirus expressed shRNA. We studied the role of SHP2 in human hematopoietic stem and progenitor cell (HSPC) function by inhibiting SHP2 expression in CB CD34+ cells utilizing shRNA directed against SHP2 ( Fig 1A) . CD34+ cells were transduced with lentivirus vectors co-expressing SHP2 specific shRNA (sh-Shp2-1 or sh-Shp2-2) or control shRNA (sh-Ctrla) with DsRED and CD34+DsRED+ cells were selected using flow cytometry ( Fig 1B) . The purity of sorted CD34+DsRED+ cells was confirmed by flow cytometry ( Fig 1C) . Expression of sh-Shp2-2 and sh-Shp-1 resulted in 81.1±0.2% and 65.0±5.3% inhibition of SHP2 expression respectively in CD34+ cells compared to control shRNA ( Fig 1D and E) . In contrast, expression of the homologous SHP1 protein was not changed in SHP2 shRNA transduced cells, indicating that knockdown was specific for SHP2.
SHP2 knockdown inhibits CD34+ cell proliferation. In view of previous reports that SHP2
may regulate hematopoietic GF signaling we investigated the effect of SHP2 knockdown on CD34+ cells response to GF stimuli. Since primary human HSPCs do not grow very well in the presence of a single GF, we studied the effect of SHP2 inhibition on the dose-response relationship of CD34+ cells to GF stimulation using a cocktail of GFs containing SCF, GM-CSF, G-CSF, IL-3 and EPO. SHP2 has been shown to be involved in the downstream signaling of these GFs in cell line studies. SHP2-knockdown CD34+dsRED+ cells cultured demonstrated markedly reduced dose-dependent proliferation following stimulation with graded concentrations of GFs in an MTS assay compared to control shRNA expressing cells (Fig 2A) . SHP2knockdown CD34+ cells also demonstrated significantly reduced expansion in cell numbers in Fig 3A) . Apoptosis was proportional to the degree of inhibition of SHP2 expression.
Although increased apoptosis was observed in all three groups on removal of GF from medium, the relative increase of apoptosis on GF deprivation compared to that seen in low GF condition was lower in SHP2 shRNA transduced cells compared with sh-Ctrla ( Fig 3B) . These observations suggest that GF-mediated promotion of cell survival is reduced in SHP2knockdown cells. Increased cell apoptosis was also seen with SHP2-knockdown cells when cultured in high concentrations of GFs compared with control ( Fig 3C) . In additional experiments we evaluated cell expansion and apoptosis of SHP2 and control shRNA transduced CD34+ cells cultured with single growth factors (SCF or Flt-3 ligand) or cytokines (IL-3 or GM-CSF) at high concentration (100ng/ml). SHP2 knockdown resulted in significantly reduced cell expansion in response to IL-3 and GM-CSF compared to control shRNA ( Fig S3A) , and decreased survival For personal use only. on April 16, 2017. by guest www.bloodjournal.org From of cells cultured with IL-3 and SCF ( Fig S3B) . These data indicating that signaling complexes involving both growth factor receptors with tyrosine kinase activities and cytokine signaling without tyrosine kinase activity may be dependent on SHP2 expression.
In order to confirm that the effects of SHP2 knockdown in hematopoietic cells were not related to "off-target" effects, we expressed a SHP2 construct with synonymous mutations in the sh-Shp2-2 targeting sequence in TF-1 cells. TF-1 cells were transduced with vectors expressing GFP (MIG-R1), wild-type SHP2 cDNA (SHP2-WT) or mutant SHP2 cDNA (SHP2-ShR) followed by transduction with vectors expressing sh-Ctrla and sh-Shp2-2 shRNA. Western blotting showed that SHP2-ShR maintained SHP2 expression in sh-Shp2-2 shRNA coexpressing cells, whereas expression of SHP2-WT only partially restored SHP2 expression in SHP2-ShR expressing cells ( Fig 4A) . Restoration of SHP2 expression by SHP2-ShR completely prevented SHP2 shRNA-mediated apoptosis and partially prevented SHP2 shRNA-mediated inhibition of cell growth (Fig 4B and C) . These results indicate that the effects of sh-Shp2-2 are related to inhibition of SHP2 expression rather than "off-target" effects.
SHP2 knockdown inhibits myeloid and erythroid differentiation of CD34+ cells.
To explore the role of SHP2 in HSPC differentiation, we cultured SHP2 shRNA and control shRNA transduced CB CD34+ cells with high concentrations of GFs (IL-3+SCF+G-CSF+GM-CSF+Epo) that promote cell differentiation towards both myeloid and erythroid lineages. Cell differentiation was detected by analyzing expression of lineage markers by using multi-color flow cytometry. SHP2 shRNA transduced CB CD34+ cells generated significantly lower numbers of both myeloid (CD11b+ and CD14+) and erythroid lineage (GPA+) cells compared with sh-Ctrla ( Fig   5A and B) , with more pronounced inhibition for myeloid lineage cells compared with erythroid lineage cells ( Fig 5C) . On the other hand, an increased percentage of CD34+ cells was seen after culture of SHP2 shRNA transduced cells, with retention of CD34+ cell numbers at levels For personal use only. on April 16, 2017. by guest www.bloodjournal.org From similar to controls ( Fig 5D) . These results suggest that GF-induced differentiation of CD34+ HSPCs is reduced after knockdown of SHP2 expression. The relative retention of the CD34+ cell population is in contrast to reduced stem cell self-renewal observed following SHP2 knockdown in murine models. Significantly reduced differentiation of SHP2-knockdown cells compared to control shRNA transduced CD34+ cells was also observed during extended culture in the condition with high concentrations of GFs ( Fig S1A) as well as under GF conditions that selectively induced myeloid differentiation (IL-3+SCF+G-CSF+GM-CSF) ( Fig S1b) or erythroid differentiation (SCF+EPO) ( Fig S1C) . To exclude the possibility of cellular senescence accounting for retention of CD34+ cells, CD34+ cells from day 7 cultures were selected using flow cytometry and stained for senescence-associated beta-galactosidase (SA-beta-Gal) and cultured with high concentration of GFs for 7 days. SHP2 shRNA and control shRNA transduced cells were both negative for SA-beta-Gal (data not shown). Interestingly SHP2 shRNA expressing CD34+ cells had higher proliferative potential in culture compared with control shRNA transduced cells ( Fig 5E) . These results indicate that the retention of the CD34+ cell population after SHP2 knockdown is not related to cellular senescence, and support the hypothesis that retention of CD34+ cells after SHP2 knockdown may be related to reduced proliferation and differentiation, which could also explain the increased proliferative potential of the retained CD34+ cells.
SHP2 knockdown inhibits engraftment of CD34+ cells in NSG mice. CB CD34+ cells
transduced with Sh-Ctrla and Sh-SHP2-2 were transplanted into sublethally irradiated NOD/SCID/γ chain null (NSG) mice. Bone marrows from mice were evaluated 8 to 14 weeks posttransplantation, and human CD45+ cell engraftment detected using flow cytometry. SHP2knockdown resulted in significantly reduced human cell engraftment in NSG mice compared to the control (P=0.012, n=18 for sh-SHP2-2 and n=6 for sh-Ctrla) (Fig S2 A and B and Table 1 ).
The relatively low engraftment efficiency of control shRNA transduced cells likely reflects effects
For personal use only. on April 16, 2017. by guest www.bloodjournal.org From of in vitro culture and manipulation required for cell transduction and selection of transduced cells. Despite this limitation, these results clearly indicate that SHP2 deficiency results in significant impairment of human HSC engraftment.
SHP2 knockdown inhibits growth factor activated ERK, AKT and Jak/STAT signaling.
SHP2 can modulate signaling mechanisms involved in hematopoietic cell survival, proliferation and differentiation, in particular ERK but also JAK/STAT and AKT signaling pathways. To study the effect of SHP2 downregulation on these cell signaling pathways we performed Western blotting for phosphorylated JAK2, STAT3, STAT5, AKT and ERK1/2 on SHP2-knockdown and control CD34+ cells after culture for 2 days ( Fig 6A) and 7 days ( Fig 6B) . SHP2 inhibition was associated with reduction of ERK1/2 and AKT phosphorylation without change in total protein levels at both early and late time points. In contrast, levels of STAT5 phosphorylation and STAT3 phosphorylation were elevated in SHP2 knockdown cells compared to controls at day 2 ( Fig 6A) ,but significantly reduced at day 7 ( Fig 6B) . Using phospho-Flow, we confirmed that phosphorylation of STAT5 (Fig 6C and S4A) and STAT3 ( Fig S4B) was increased in CD34+ cells at early but not late time points after culture. In addition, SHP2-knockdown resulted in reduction in phosphorylated JAK2 (Y1007/Y1008) at day 2 and in phosphorylated and total JAK2 levels at day 7. Expression of the anti-apoptotic genes BCLXL and MCL1, which are known to be regulated by STAT5 and ERK respectively 30, 31 , were also decreased in SHP2knockdown CD34+ cells, with greater inhibition of MCL1 and BCLXL expression in sh-Shp2-2 compared with sh-Shp2-1 expressing cells ( Fig 6D) . In contrast BCL2 expression was increased compared with control in sh-Shp2-2 expressing cells, These results suggest a potential role for these signaling mechanisms in the reduced GF mediated proliferation, differentiation and survival of SHP2-knockdown cells.
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Effect of SHP2 knockdown on cells expressing gain of function SHP2 mutants.
Since our results suggested that therapeutic SHP2 inhibition could be associated with significant hematopoietic toxicity, it was of interest to examine whether cell expressing gain-of-function mutations in SHP2 demonstrated enhanced sensitivity to SHP2 inhibition. To examine this we expressed a leukemia-associated SHP2 gain-of-function mutant (E76K) and wild type SHP2 in TF-1 hematopoietic cells to evaluate the relative effect of SHP2 knockdown on survival of mutant versus wild type SHP2 expressing cells. E76K expressing cells transduced with sh-Shp2-2 expressing vectors demonstrated increased apoptosis following SHP2 knockdown and similar inhibition of growth compared to wild-type SHP2 expressing cells ( Figure 7A and B) .
These results suggest that cells expressing gain-of-function SHP2 mutations may have increased dependency on SHP2 expression for survival and may be more sensitive to inhibition of SHP2 expression or function.
Discussion
In this study we employed SHP2 specific shRNAs delivered by lentiviral vectors to knockdown shRNA in this setting may be explained by previous observations that overexpression of wildtype SHP2 can negatively affect GF signaling and cell growth. 14, 32 Alternatively our data may indicate that SHP2 regulation of hematopoietic cell growth and survival may occur through different pathways. In murine models SHP2 deletion is associated with reduced stem cell selfrenewal. 9 In contrast, we observed relative retention of CD34+ cells in SHP2 knockdown cells with retention of enhanced proliferative potential and without significant cell senescence.
Retention of primitive cells following SHP2 knockdown could result from reduced CD34+ cell division and differentiation. On the other hand SHP2 knockdown human cells demonstrated
reduced engraftment in NSG mice suggesting impaired stem cell capacity. It is unclear whether this reflects altered homing and engraftment capacity, or reduced proliferation and differentiation capacity of SHP2 knockdown cells, which could limit our ability to detect stem cell engraftment. SHP2 catalytic activity is required for promotion of signaling through the Ras-ERK and PI-3K pathway. SHP2 may associate with GF receptors directly by docking to phosphorylated tyrosine residues or indirectly via adaptor/scaffolding proteins, such as GAB2, which possess conserved tyrosine sites for engagement of the two SHP2 SH2 domains. 16, 33 Although the key substrates for Ras-ERK activation remain unknown, SHP2-mediated dephosphorylation and inhibition of negative regulators including RasGAP and sprouty proteins, or dephosphorylation and activation of Src kinase, may play a role. In our studies SHP2 inhibition in hematopoietic cells was associated with reduced ERK and AKT activation, suggesting a role for SHP2 in GFmediated activation of ERK and PI-3K/AKT signaling in normal hematopoietic cells. SHP2 has been reported to both enhance and inhibit signaling in the JAK/STAT pathway, depending on the cell context and extracellular signals. 34 SHP2 can negatively regulate STAT family proteins in different cell types through direct dephosphorylation of tyrosine-phosphorylated STATs and/or downregulation of upstream JAK kinases. [35] [36] [37] [38] On the other hand SHP2 can dephosphorylate the Tyr1007 site in JAK2 and prevent subsequent degradation of JAK2, 39 and can promote STAT5 activation and up-regulate STAT5 target gene expression. 40 Our results indicate that SHP2 knockdown has complex effects on STAT5 signaling in human hematopoietic progenitors. SHP2 knockdown is initially associated with increased STAT5 and STAT3 phosphorylation despite reduced Jak2 phosphorylation, likely related to loss of SHP2-mediated dephosphorylation of STAT5 35 and STAT3 41 proteins. Reduced Jak2 phosphorylation may reflect the ability of SHP2 to act immediately downstream of GF receptors to facilitate JAK2 activation. 40 On the other hand chronic knockdown of SHP2 resulted in significantly reduced phosphorylated STAT5 and STAT3 suggesting activation of counter-regulatory mechanisms such as other protein-tyrosine phosphatases (PTP), suppressors of cytokine signaling (SOCS), and protein inhibitors of activated STATs (PIAS). 42, 43 . Reduced total JAK2 levels with chronic SHP2 knockdown may reflect enhanced proteasomal degradation of JAK2 due to activation of counter-regulatory proteins such as SOCS1 and SOCS3. 44, 45 . Flow cytometry based measurement of P-STAT5 in CD34+ expressing cells confirmed increased STAT5 phosphorylation at day 3 but not at day 5 of culture, indicating that these time-dependent changes did not simply reflect the increased numbers of differentiated cells over time.
We observed that higher degrees of chronic SHP2 knockdown result in increased inhibition of STAT5 activation in hematopoietic cells. Since increased SHP2 knockdown was associated with increased apoptosis and inhibition of proliferation of myeloid and erythroid cells, these observations suggest an important contribution of STAT5 activation in mediating SHP2 effects on hematopoietic progenitor viability and proliferation. We further demonstrated that higher degrees of SHP2-knockdown resulted in reduced levels of MCL1 and BCLXL in hematopoietic cells in association with reduced STAT5 activation. MCL1 is a BCL2 family member that plays a For personal use only. on April 16, 2017. by guest www.bloodjournal.org From critical role in HSC survival. 46 Levels of MCL1 and BCLXL, but not BCL2, in hematopoietic cells are regulated by survival signals from cytokines. 47 STAT5 signaling up-regulates MCL1 and BCLXL expression by directly activating transcription, 30, 48 and can also up-regulate MCL1 at the protein level by activating the PI3K/AKT pathway. 48 These results suggest that SHP2 effects on hematopoietic cell viability may be mediated by inhibition of MCL1 and BCLXL downstream of JAK2 and STAT5. Previous studies have shown that knockdown of STAT5 in cord blood CD34+ cells results in significantly reduced cell proliferation and colony formation without significant effects on cell differentiation and cell apoptosis. 49 The additional effects of SHP2 knockdown on downstream signaling pathways including JAK2, STAT3, ERK and AKT, may explain the more extensive effects of SHP2 knockdown on cell growth compared with STAT5 knockdown alone.
There is continued interest in evaluation of SHP2 as a therapeutic target and the development of small molecule SHP2 inhibitors. 50 The results of the current studies caution that therapeutic SHP2 inhibition could be associated with significant hematopoietic toxicity. On the other hand we made the important observation that cells expressing a SHP2 gain-of-function mutant exhibited higher levels of apoptosis following SHP2 knockdown compared to cells expressing wild-type SHP2. These results indicate that cells dependent on gain-of-function SHP2 mutations may be more sensitive to the pro-apoptotic effects of SHP2 inhibition. The mechanisms underlying this differential sensitivity is unclear at present. These observations support further study to confirm that malignant cells demonstrate greater dependence on SHP2 and enhanced sensitivity to SHP2-specific inhibitors compared to normal cells. It will also be important to determine whether transient or intermittent inhibition of SHP2 may be sufficient to target tumor cells but less toxic to normal hematopoietic cells compared with constitutive knockdown of SHP2 as in the present study. 
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